Outlook Therapeutics Plummets 54%: What's Fueling the Bloodbath in Biotech?

Summary
• OTLK opens at $0.7905, plummets to $0.79 intraday before rallying to $1.0901
• 59.8M shares traded—218.5% surge in turnover
• MACD histogram narrows to 0.028 as RSI stabilizes at 60.04
• Options frenzy: 30757 contracts traded in 2025-11-21 $1 strike calls
Outlook Therapeutics is hemorrhaging value in a single session, with technical indicators and options data painting a picture of extreme volatility. The stock's 54% drop from previous close to current price has triggered a cascade of stop-losses and leveraged bets, while the biotech sector remains cautiously watchful.

Options Gamma Squeeze and Short-Term Bearish Momentum
The collapse in OTLK is driven by a combination of technical exhaustion and options market dynamics. The stock's 52-week range of $0.79–$8.32 has created a psychological floor at $1.00, where the 200-day MA (2.039) and 30D support (1.998–2.021) now act as distant ghosts. With RSI at 60.04 and MACD signal line crossing above 0.146, the short-term bearish momentum is reinforced by the 2025-11-21 $1 strike put options (OTLK20251121P1) showing 109.58% implied volatility and 0.649 gamma sensitivity. The 92% volume in these puts suggests aggressive short-term bearish positioning.

Bearish Gamma Play and Short-Term Hedging Opportunities
• 200-day MA: 2.039 (far above current price)
• RSI: 60.04 (neutral territory)
• Bollinger Bands: 1.578–2.961 (current price at 1.09, below lower band)
• Turnover rate: 218.5% (extreme liquidity)
• MACD: 0.174 (bullish divergence narrowing)
• Key support: 1.47–1.58 (200D range)
• Sector leader AMGN -0.78% (limited sector correlation)
• Top options:
• OTLK20251121P1 (Put): 109.58% IV, 5.92% leverage, -0.343 delta, 0.649 gamma, 2604 turnover
• OTLK20251121C1 (Call): 160.37% IV, 3.04% leverage, 0.685 delta, 0.428 gamma, 30757 turnover
For a 5% downside scenario (ST=1.0356), OTLK20251121P1 payoff would be max(0, 1.0356-1)=0.0356, while OTLK20251121C1 would expire worthless. The put option's high gamma (0.649) and moderate delta (-0.343) make it ideal for capitalizing on further volatility. Aggressive short-sellers should consider OTLK20251121P1 as a near-term bearish play, while OTLK20251121C1 offers liquidity for hedging rallies. Watch for breakdown below 1.47 support or a reversal above 1.58 resistance.

Backtest Outlook Therapeutics Stock Performance
Query limit exceeded.

Critical Support Levels and Gamma-Driven Volatility
OTLK's 54% intraday drop has created a volatile environment where technical indicators and options gamma dynamics dominate. With RSI stabilizing at 60.04 and Bollinger Bands indicating oversold conditions, the immediate focus should be on the 1.47–1.58 support/resistance range. The 2025-11-21 $1 put option (OTLK20251121P1) remains a high-probability play for short-term bearish positioning, while sector leader AMGN's -0.78% decline suggests biotech remains cautiously bearish. Investors should prioritize liquidity in OTLK20251121P1 and monitor the 1.00 psychological level—break below 1.00 triggers a new short-term bearish phase.